Novel therapies in the treatment of ulcerative colitis

Expert Opinion on Investigational Drugs

Volumn 12, Issue 3, 2003, Pages 483-490

  Tulvin, Jeffrey A ^a   Kane, Sunanda V ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cytokines; Therapy; Ulcerative colitis

Indexed keywords

3,4 DIHYDRO 4,4 DIMETHYL 1,3 BENZOSELENAZINE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AZATHIOPRINE; BASILIXIMAB; BETA INTERFERON; BOWMAN BIRK INHIBITOR; CBP 1011; DACLIZUMAB; DELIGOPARIN; HEPARIN DERIVATIVE; INFLIXIMAB; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ANTIBODY; KERATINOCYTE GROWTH FACTOR; MEDROXYPROGESTERONE ACETATE; MERCAPTOPURINE; MESALAZINE; MONOCLONAL ANTIBODY; PREDNISOLONE 3 SULFOBENZOATE; PROBIOTIC AGENT; REPIFERMIN; RIFAMIXIN; ROSIGLITAZONE; STEROID; TACROLIMUS; TIOGUANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEPOLIMOMAB; VISILIZUMAB;

ADRENAL SUPPRESSION; APHERESIS; BONE MARROW TOXICITY; CHRONIC INFLAMMATION; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG FORMULATION; DRUG METABOLISM; DRUG TOLERABILITY; GENETICS; HUMAN; IMMUNOLOGY; LIVER TOXICITY; MAINTENANCE THERAPY; NAUSEA; NONHUMAN; PANCREATITIS; RELAPSE; REMISSION; REVIEW; SIDE EFFECT; ULCERATIVE COLITIS; VERTIGO;

ADJUVANTS, IMMUNOLOGIC; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIOXIDANTS; AZOLES; BLOOD COMPONENT REMOVAL; CLINICAL TRIALS; COLITIS, ULCERATIVE; CYTOKINES; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTORS; HORMONES; HUMANS; ORGANOSELENIUM COMPOUNDS; PROBIOTICS; PROTEASE INHIBITORS;

EID: 0037339335     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.3.483     Document Type: Review

References (78)

1. LOFTUS EV Jr, SILVERSTEIN MD, SANDBORN WJ, TREMAINE WJ, HARMSEN WS, ZINSMEISTER AR: Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut (2000) 46:336-343.
2. SHIVANANDA S, LENNARD-JONES J, LOGAN R et al.: Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut (1996) 39:690-697.
3. TRALLORI G, PALLI D, SAIEVA C et al.: A population-based study of inflammatory bowel disease in Florence over 15 years (1978-92). Scand. J. Gastroenterol. (1996) 31:892-899.
4. SATSANGI J, GROOTSCHOLTEN C, HOLT H, JEWELL DP: Clinical patterns of familial inflammatory bowel disease. Gut (1996) 38:738-741.
5. PARKES M, BARMADA MM, SATSANGI J, WEEKS DE, JEWELL DP, DUERR RH: The IBD2 locus shows linkage heterogeneity between ulcerative colitis and Crohn disease. Am. J. Hum. Genet. (2000) 67:1605-1610.
6. DUERR RH, BARMADA MM, ZHANG L et al.: Linkage and association between inflammatory bowel disease and a locus on chromosome 12. Am. J. Hum. Genet. (1998) 63:95-100.
7. HUGOT JP, THOMAS G: Genome-wide scanning in inflammatory bowel diseases. Dig. Dis. (1998) 16:364-369.
8. TYSK C, LINDBERG E, JARNEROT G, FLODERUS-MYRHED B: Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins: a study of heritability and the influence of smoking. Gut (1988) 29:990-996.
9. ORHOLM M, MUNKHOLM P, LANGHOLZ E, NIELSEN O, SORENSEN TIA, BINDER V: Familial occurrence of inflammatory bowel disease. N. Engl. J. Med. (1991) 324:84-88.
10. SANDLER RS, WURZELMANN JI, LYLES CM: Oral contraceptive use and the risk of inflammatory bowel disease. Epidemiology (1992) 3:374-378.
11. ANDERSSON R, OLAISON G, TYSK C, EKBOM A: Appendectomy and protection against ulcerative colitis. N. Engl. J. Med. (2001) 344:808-814.
12. EVANS J, MCMAHON A, MURRAY F, McDEVITT D, MACDONALD T. Non-steroidal anti-inflammatory drugs are asoociated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut (1997) 40:619-622.
13. COSNES J, BEAUGERIE L, CARBORNELL F, GENDRE J: Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology (2001) 120:1093-1099.
14. LINDBERG E, TYSK C, ANDERSSON K, JARNEROT G: Smoking and inflammatory bowel disease: a case control study. Gut (1988) 29:352-357.
15. RATH H, SCHULTZ M, FREITAG R et al.: Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect. Immun. (2001) 69:2277-2285.
16. ELSON C: Experimental models of intestinal inflammation: new insights into mechanisms of mucosal homeostasis. In: Mucosal Immunology (2nd Ed.). P Ogra, J Mestecky, M Lamm, W Strober, J Bienstock, J McGhee (Eds), Academic Press, San Diego, CA, USA (1999):1007-1024.
17. HANAUER SB: Inflammatory bowel disease. N. Engl. J. Med. (1996) 334:841-848.
18. KORNBLUTH A, SACHAR DB: Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol. (1997) 92:204-211.
19. GIONCHETTI P, RIZZELLO F, VENTURI A et al.: Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis. Colon Rectum (1998) 41:93-97.
20. SAFDI M, DEMICCO M, SNINSKY C et al.: A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am. J. Gastroenterol. (1997) 92:1867-1871.
21. KIRK AP, LENNARD-JONES JE: Controlled trial of azathioprine in chronic ulcerative colitis. Br. Med. J. (Clin. Res. Ed.) (1982) 284:1291-1292.
22. PRESENT DH, MELTZER SJ, KRUMHOLZ MP, WOLKE A, KORELITZ BI: 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann. Intern. Med. (1989) 111:641-649.
23. LICHTIGER S, PRESENT DH, KORNBLUTH SA et al.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. (1994) 330:1841-1845.
24. MANTAZARIS G, HATZIS A, KONTOGIANNIS P, TRIADAPHYLLOU G: Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. (1994) 89:43-46.
25. MANTAZARIS G, ARCHAVLIS E, CHRITOFORDIS P, AL E: A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. (1997) 92:454-456.
26. TURUNEN UM, FARKKILA MA, HAKALA K et al.: Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology (1998) 115:1072-1078.
27. PODOLSKY D: Inflammatory bowel disease. N. Engl. J. Med. (2002) 347:417-419.
28. MURCH SH, LAMKIN VA, SAVAGE MO, WALKER-SMITH JA, MACDONALD TT: Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut (1991) 32:913-917.
29. SANDS BE, TREMAINE WJ, SANDBORN WJ et al.: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm. Bowel Dis. (2001) 7:83-88.
30. CHEY WY, HUSSAIN A, RYAN C, POTTER GD, SHAH A: Infliximab for refractory ulcerative colitis. Am. J. Gastroenterol. (2001) 96:2373-2381.
31. PROBERT C, HEARING S, SCHREIBER S, KUHBACHER T, GHOSH S, FORBES A: Infliximab in Steroid-resistant Ulcerative Colitis: A Randomised Controlled Trial. (2002):A-99.
32. SU C, SALZBERG B, LEWIS J et al.: Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am. J. Gastroenterol. (2002) 97:2576-2584.
33. VAN ASSCHE G, DALLE I, NOMAN M, AERDEN I, AL E: The use of humanized anti interleukin-2 receptor antibodies (zenapax, Roche) in refractory ulcerative colitis. Gastroenterology (2001) 120:A-279.
34. CLAESSENS C, VANASSCHE G, DALLE I, D'HAENS G, GEBOES K, RUTGEERTS PJ: Clinical improvement precedes mucosal healing in ulcerative colitis treated with anti-IL-2 agents. Gastroenterology (2002):A-431.
35. HEARING S, CROWLEY C, CREED T, NORMAN M, DAYAN C: Steroid enhancing effect of the interleukin-2 antagonist basiliximab on lymphocyte steroid sensitivity. Gastroenterology (2002) A-400.
36. SELBY WS, JANOSSY G, BOFILL M, JEWELL DP: Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation techniques. Gut (1984) 25:32-40.
37. HIRATA I, BERREBI G, AUSTIN, LL, KEREN DF, DOBBINS WO 3rd: Immunohistological characterization of intraepithelial and lamina propria lymphocytes in control ileum and colon and in inflammatory bowel disease. Dig. Dis. Sci. (1986) 31:593-603.
38. SCHREIBER S, MACDERMOTT RP, RAEDLER A, PINNAU R, BERTOVICH MJ, NASH GS: Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease. Gastroenterology (1991) 101:1020-1030.
39. JAMES SP: Remission of Crohn's disease after human immunodeficiency virus infection. Gastroenterology (1988) 95:1667-1669.
40. DEUSCH K, MAUTHE B, REITER C, REITHMULLER G, CLASSEN M: Chimeric monoclonal anti-CD4 antibody therapy proves effective for treating inflammatory bowel disease. Gastroenterology (1992):A615.
41. DEUSCH K, REITER C, MAUTHE B, RIETHMULLER G, CLASSEN M: CD4-antibody treatment of inflammatory bowel disease: one-year follow up. Gastroenterology (1993) 104:A691.
42. EMMRICH J, SEYFARTH M, FLEIG WE, EMMRICH F: Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody. Lancet (1991) 338:570-571.
43. EMMRICH J, SEYFARTH M, LIEBE S, EMMRICH F: Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody. Gastroenterology (1992) 102-A620.
44. +-cell depletion. Gastroenterology (1995) 108:A815.
45. COLE M, ANASETTI C: Human IgG2 Variants of chimeric anti-CD3 are non-mitogenic to T cells. J. Immunol. (1997) 159:3613.
46. COLE M.S, STELLRECHT KE, SHI JD et al.: HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation (1999) 68:563-71.
47. NORMAN DJ, VINCENTI F, DE MATTOS AM et al.: Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation (2000) 70:1707-1712.
48. CARPENTER PA, APPELBAUM FR, COREY L et al.: A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood (2002) 99:2712-2719.
49. BARON S, TYRING SK, FLEISCHMANN WR Jr et al.: The interferons. Mechanisms of action and clinical applications. JAMA (1991) 266:1375-1383.
50. NIKOLAUS S, RUTGEERTS PJ, FEDORAK R, STEINHEART H, WILD G, AL E: Recombinant human interferon-beta (IFNbeta-1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology (2001) 120:A-454.
51. MUSCH E, RAEDLER A, ANDUS T et al.: A Phase II placebo-controlled, randomized, multicenter study to evaluate efficacy and safety of interferon beta-1a in patients with ulcerative colitis. Gastroenterology (2002) T1195:A-431.
52. SUMER N, PALABIYIKOGLU M: Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur. J. Gastroenterol. Hepatol. (1995) 7:597-602.
53. MADSEN SM, SCHLICHTING P, DAVIDSEN B et al: An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am. J. Gastroenterol. (2001) 96:1807-1815.
54. ARONCHICK C, DALKE D, IONNA S, RIFF D, SCHIFF M: Medroxyprogesterone acetate is effective in the treatment of ulcerative colitis. Gastroenterology (2001) 120:A455.
55. LUKAS M, KONECNY M, ZBORIL V: Rifamixin in patients with mild to moderate activity of ulcerative colitis: an open label study. Gastroenterology (2002) T1214:A-434.
56. BAUMGART D, PASCU M, WIEDENMANN B, DIGNASS A: Rescue therapy with tacrolimus (FK506) is highly effective in patients with severe and refractory inflammatory bowel disease. Gastroenterology (2002) T1211:A-434.
57. BONAZ B, BOITARD J, MARTEAUE P. LEMANN M: 6-Thioguanine in patients intolerant to 6-mercaptopurine/azathioprine. Gastroenterology (2002) T1202:A-432.
58. HERRLINGER K, KREISEL W, SCHWAB M, FISCHER C, AL E: Open prospective trial on 6-thioguanine for chronic active Crohn's Disease. Gastroenterology (2002) T1203:A-432.
59. DE JONG D, DERIJKS L, ENGELS L, JANSEN J, HOOYMANS P, MULDER C: 6-Thioguanine seems promising in azathioprine introlerant patients. Gastroenterology (2002) T1201:A-432.
60. THOMPSON R, BLOOR J, EDE R et al.: Preserved endogenous cortisol levels during treatment of ulcerative colitis with COLALPRED, a novel oral system consistently delivering prednisolone metasulphobenzoate to the colon. Gastroenterology (2002) T1207:A-433.
61. GIONCHETTI P, RIZZELLO F, VENTURI A et al.: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology (2000) 119:305-309.
62. VENTURI A, GIONCHETTI P, RIZZELLO F et al.: Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol, Ther. (1999) 13:1103-1108.
63. KRUIS W, SCHUTZ E, FRIC P, FIXA B, JADMAIER G, STOLTE M: Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol. Ther. (1997) 11:853-858.
64. REMBACKEN B, SNELLING A, HAWKEY P, CHALMERS D, AXON AT: Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet (1999) 354:635-639.
65. MICELI R, HUBERT M, SANTIAGO G et al.: Efficacy of keratinocyte growth factor-2 in dextran sulfate sodium-induced murine colitis. J. Pharmacol. Exp. Ther. (1999) 290:464-471.
66. HAN DS, LI F, HOLT L et al.: Keratinocyte growth factor-2 (FGF-10) promotes healing of experimental small intestinal ulceration in rats. Am. J. Physiol. Gastrointest. Liver Physiol. (2000) 279:G1011-G1022.
67. SANDBORN WJ, SANDS BE, WOLF D et al.: Repifermin (keratinocyte growth factor 2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Gastroenterology (2002) 507:A-61.
68. HANAUER SB, MINER P, KESHAVARZIAN A, MORRIS E, SALZBERG B, BENNETT M: Phase II study of safety, efficacy, and pharmokinetics of BXT-51072 in patients with mild-moderately active ulcerative colitis. Gastroenterology (2001) 120:A-280.
69. RICE KD, WANG VR, GANGLOFF AR et al.: Dibasic inhibitors of human mast cell tryptase. Part 2: structure-activity relationships and requirements for potent activity. Bioorg. Med. Chem. Lett. (2000) 10:2361-2366.
70. WARE JH, WAN, XS, NEWBERNE P, KENNEDY AR: Bowman-Birk inhibitor concentrate reduces colon inflammation in mice with dextran sulfate sodium-induced ulcerative colitis. Dig. Dis. Sci. (1999) 44:986-990.
71. LICHTENSTEIN GR, DEREN J, KATZ S, KENNEDY AR, WARE JH: The bowman pick protease inhibitor: a novel therapy for treatment of patients with active ulcerative colitis. Gastroenterology (2002) 122:A-60.
72. MANGELSDORF DJ, THUMMEL C, BEATO M et al.: The nuclear receptor superfamily: the second decade. Cell (1995) 83:835-839.
73. SU CG, WEN X, BAILEY ST et al.: A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J. Clin. Invest. (1999) 104:383-389.
74. DUBUQUOY L, BOURDON C, PEUCHMAUR M et al.: [Peroxisome proliferator-activated receptor (PPAR) gamma: a new target for the treatment of inflammatory bowel disease]. Gastroenterol. Clin. Biol. (2000) 24:719-724.
75. LEWIS JD, LICHTENSTEIN GR, STEIN RB et al.: An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am. J. Gastroenterol. (2001) 96:3323-3328.
76. HANAI H, WATANABE F, MATSUSHIDA I, TAKEUCHI K, LIDA T, AL E: Granulocyte and Monocyte Adsorption Apheresis in Patients with Severe Corticosteroid Unresponsive Ulcerative Colitis. Gastroenterology (2002) T1198:A-431.
77. KANNKE K, NAKANO M, TAKESHI O, YUKIO O, YASUNAGA S, AL E: Granulocyte and monocyte adsorption apheresis as an effective adjunct to conventional medications to promote remission and reduce corticosteroid dose in patients with active ulcerative colitis. Gastroenterology (2002) T1199:A-432.
78. KAWAMURA N, OHTA K, MIURA Y, NAKAI Y, TSUYUGUCHI M, AL E: Efficacy of the leucocyte apheresis with the use of the nonwoven polyester filter in ulcerative colitis. Gastroenterology (2002) T1196:A-431.